In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Roche NimbleGen Inc.

Division of Roche

Latest From Roche NimbleGen Inc.

Roche Pounces On Market-Weakened Illumina

Roche’s $5.7 billion hostile takeover offer for Illumina is opportunistic as well as strategic. It is a validation of Illumina’s long-term growth potential but also takes advantage of a depressed stock price due to the global economic slowdown and cutbacks in government funding that have hurt Illumina and other providers of gene sequencing instrumentation.

Medical Device BioPharmaceutical

Cellular Dynamics Pulls In $40 Million

Cellular Dynamics International, which manufactures human cells for drug assays,has tapped a closely connected syndicate of investors for nearly $41 million in Series B funding, bringing total investment in the firm to $70 million. The fundraising total is impressive for a start-up in a highly speculative area of biotech where VCs have been cautious about committing capital.
BioPharmaceutical Regenerative Medicine

Archemix Reduces Aperture to Pursue Orphan Diseases

Archemix has consolidated IP in the aptamer space and enjoyed success in partnering its technology. But public markets have frozen the company out and it is now focusing on orphan hematologic diseases. The move should help the company conserve cash while creating earlier out-licensing opportunities as Archemix transitions into later-stage development.
BioPharmaceutical Strategy

In Vitro Diagnostics: Innovation and Integration

Integration is occuring at almost every level of the in vitro diagnostic industry--at the preclinical level to decrease drug development costs and timelines and at the clinical level to better manage diseases. In the lab, there's a demand for new tools to improve speed and efficiency, and new information systems to better integrate disparate data. At the same time, there has been a flurry of integration and consolidation at the market level, with 35 mergers and acquisitions in the last 12 months.
Medical Device
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • NimbleGen Systems Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Roche
  • Senior Management
  • Stanley Rose, PhD, Pres. & CEO
    Roland Green, PhD, VP, R&D, & CTO
    Emile Nuwaysir, PhD, VP, Bus. Dev.
    Dan Clutter, PhD, VP, Sales
  • Contact Info
  • Roche NimbleGen Inc.
    Phone: (608) 218-7600
    One Science Ct.
    Madison, WI 53711